GlassScriptPhysician profile
Sepehr Nowfar
NPI 1124174560
$20,058.53
in general payments reported to CMS, 2019-2025
66 companies · $3,620 in 2025
The $3,620 reported for 2025 was more than what 88% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $511 · 2021: $1,151 · 2022: $2,263 · 2023: $8,615 · 2024: $3,242 · 2025: $3,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,318 · Food and Beverage: $6,365 · Honoraria: $1,200 · Travel and Lodging: $493 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,317.50 |
| Food and Beverage | $6,364.62 |
| Honoraria | $1,200.00 |
| Travel and Lodging | $493.29 |
| Education | $101.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $9,098.87 | 2021-2025 | Urolift, Barrigel, Solesta |
| Dendreon Pharmaceuticals LLC | $1,578.10 | 2020-2025 | Provenge |
| Janssen Scientific Affairs, LLC | $1,099.62 | 2024-2025 | Erleada |
| Coloplast Corp | $723.17 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $593.74 | 2023-2025 | Orgovyx, Gemtesa |
| Cook Incorporated | $500.00 | 2024 | |
| Janssen Global Services, LLC | $500.00 | 2025 | |
| Janssen Biotech, INC. | $443.49 | 2019-2025 | Erleada, Balversa |
| Myriad Genetic Laboratories, INC. | $368.86 | 2021-2024 | Prolaris |
| Urogen Pharma, INC. | $334.74 | 2021-2025 | |
| Abbvie INC. | $328.48 | 2019-2025 | |
| Astellas Pharma US INC | $294.76 | 2019-2025 | Xtandi |
| Endo Pharmaceuticals INC. | $278.60 | 2019-2023 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $277.12 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Myovant Sciences INC. | $254.18 | 2021-2022 |
Show all 65 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sepehr Nowfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.